Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 72 of 114

  1. P160913

    Pari Pharma GmbH

    Adults patients with isolated acute urticaria presenting to the emergency department

    phase 3 small molecule active

    1 trial

  2. P160924

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  3. P160925J

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  4. P160931J

    Pari Pharma GmbH

    Adult patients with ulcerative colitis diagnosed for at least 3 months

    phase 3 small molecule active

    1 trial

  5. P170912J

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  6. P170913J

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  7. P170916J

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  8. P170923J

    Pari Pharma GmbH

    gender dysphoria

    phase 3 small molecule active

    1 trial

  9. P170938J

    Pari Pharma GmbH

    Asplenia

    phase 3 small molecule active

    1 trial

  10. PA0016

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  11. PACIFIC2/D933KC00001

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  12. PANC-CAP-3001

    Lacuna Pharma Pty Ltd

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

  13. PAPA-Can

    Istituto Gentili S.r.l.

    PAPA syndrome

    phase 3 small molecule active

    1 trial

  14. PBO PH20 SC, ARGX-113

    argenx

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  15. PBP-301

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  16. PBSCs

    Hospital Authority, Hong Kong

    Hematological Malignancies

    phase 3 other completed

    1 trial

  17. PB_A&A-ASC-FISTULA_1

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  18. PCSK9 inhibitors combined with atorvastatin/rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  19. PCV21

    Sanofi Pasteur

    Pneumococcal Infections

    phase 3 mab active

    1 trial

  20. PCV21 vaccine

    Sanofi Pasteur

    Pneumococcal Immunization

    phase 3 mab active

    1 trial

  21. PD-0332991

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  22. PDS Implant with Ranibizumab 100 mg/mL

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  23. PEAK-1

    Arcus Biosciences

    Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  24. PEDIADEX

    Tour Hekla

    Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

    phase 3 small molecule active

    1 trial

  25. PEG-Interferon a-2b + Ribavirin

    Universal Integrated

    Chronic Hepatitis C Infection in HIV-Infected Persons

    phase 3 small molecule completed

    1 trial

  26. PEG-interferon-Alfa-2A

    Hospital Authority, Hong Kong

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  27. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  28. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  29. PEGylated Recombinant Factor VIII

    Takeda

    Hemophilia A

    phase 3 mab completed

    2 trials

  30. PEGylated Recombinant factor VIII (rFVIII)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  31. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  32. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  33. PEMBROLIZUMAB , BNT113

    BioNTech SE

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial

  34. PF-02341066

    Pfizer

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    2 trials

  35. PF-05280014

    Pfizer

    Metastatic Breast Cancer

    phase 3 mab completed

    1 trial

  36. PF-05280586

    Pfizer

    Follicular Lymphoma

    phase 3 mab completed

    1 trial

  37. PF-06438179

    Pfizer

    Rheumatoid Arthritis

    phase 3 mab completed

    1 trial

  38. PF-06651600 Induction Dose

    Pfizer

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  39. PF-06801591

    Pfizer

    Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  40. PF-07275315 dose 1

    Pfizer

    Moderate to Severe Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  41. PF-07321332

    Pfizer

    COVID-19

    phase 3 small molecule completed

    2 trials

  42. PF614 capsule

    Ensysce Biosciences

    Postoperative Pain, Acute

    phase 3 small molecule active

    1 trial

  43. PG-011 nasal spray 0.6%(twice daily)

    Prime Medicine

    Seasonal Allergic Rhinitis

    phase 3 small molecule active

    1 trial

  44. PG-011Gel

    Prime Medicine

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  45. PGET

    Atrium Therapeutics

    Osteoarthritis

    phase 3 other terminated

    1 trial

  46. PH-L19TNFDOX2-03/16

    Philogen S.p.A.

    Unresectable or metastatic soft tissue sarcoma

    phase 3 small molecule active

    1 trial

  47. PH94B

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    1 trial

  48. PH94B Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.